N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial

. 2023 Sep 13;20:209. doi: 10.1186/s12974-023-02893-9

Aim	Measure
To evaluate oral GlcNAc effects on serum neurofilament light chain (sNfL) To evaluate oral GlcNAc effects on clinical disability	Serum from individuals before, during and after oral GlcNAc therapy was assessed for changes in sNfL using SIMOA (Quanterix) EDSS was assessed pre-treatment (study visits 1 and 4), at the end of 4 weeks of oral GlcNAc (study visit 8) and 4 weeks after stopping treatment (study visit 11)

Aim

Measure

To evaluate oral GlcNAc effects on serum neurofilament light chain (sNfL)

To evaluate oral GlcNAc effects on clinical disability

Serum from individuals before, during and after oral GlcNAc therapy was assessed for changes in sNfL using SIMOA (Quanterix)

EDSS was assessed pre-treatment (study visits 1 and 4), at the end of 4 weeks of oral GlcNAc (study visit 8) and 4 weeks after stopping treatment (study visit 11)